Data completeness—the Achilles heel of drug-target networks

[1]  J. Mestres,et al.  A ligand-based approach to mining the chemogenomic space of drugs. , 2008, Combinatorial chemistry & high throughput screening.

[2]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[3]  A. Bender,et al.  Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data , 2007, ChemMedChem.

[4]  A. Barabasi,et al.  The human disease network , 2007, Proceedings of the National Academy of Sciences.

[5]  Sherry L. Jenkins,et al.  Network analysis of FDA approved drugs and their targets. , 2007, The Mount Sinai journal of medicine, New York.

[6]  G. V. Paolini,et al.  Global mapping of pharmacological space , 2006, Nature Biotechnology.

[7]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[8]  E. Kunkel.  Systems biology in drug discovery , 2004, Nature Biotechnology.

[9]  B. Roth,et al.  Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.

[10]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[11]  S. Lovell,et al.  Protein-protein interaction networks and biology—what's the connection? , 2008, Nature Biotechnology.

[12]  David E. Gloriam,et al.  ProteomeBinders: planning a European resource of affinity reagents for analysis of the human proteome , 2007, Nature Methods.

[13]  Tudor I. Oprea,et al.  Chemoinformatics in drug discovery , 2005 .